Revance Therapeutics

Revance is more than a biotechnology company with a novel drug-delivery platform. We are the integrated sum of our many strengths.

Deep knowledge of drug development, scientific acumen, and prior commercialization experience will enable our team of experts to bring to market a focused portfolio of products that achieve multiple strategic objectives.

We like to dream and think big. Our organization owns aspirations of becoming a global leader in both aesthetic medicine and underserved therapeutic specialties such as as dermatology, neurology, urology, and ophthalmology.

Currently, Revance is advancing two investigational product candidates. Each has the potential to expand practitioner and patient utilization, with the opportunity to capture, retain and grow significant market share.

While our first indications will be used in aesthetic medicine to treat facial wrinkles, we plan to follow with improved therapeutic options that deliver enhanced results, irrespective of use area. Our ultimate mission is to improve the overall patient experience. We know it can be done and we aim to prove it.

Company Growth (employees)
Type
Public
HQ
Newark, US
Size (employees)
106 (est)+3%
Revance Therapeutics is headquartered in Newark, US

Revance Therapeutics Office Locations

Revance Therapeutics has an office in Newark
Newark, US (HQ)
7555 Gateway Blvd

Revance Therapeutics Data and Metrics

Revance Therapeutics Financial Metrics

Revance Therapeutics's revenue was reported to be $300 k in FY, 2016
$, USD

Revenue (FY, 2016)

300 k

Net income (FY, 2016)

(89.3 m)

EBIT (FY, 2016)

(88.2 m)

Market capitalization (23-Jun-2017)

799.2 m

Closing share price (23-Jun-2017)

26.5

Cash (31-Dec-2016)

63.5 m
Revance Therapeutics's current market capitalization is $799.2 m.
$, USDFY, 2014FY, 2015FY, 2016

Revenue

383 k300 k300 k

Revenue growth, %

(22%)

R&D expense

47.5 m50.4 m

General and administrative expense

25.1 m29.1 m

Operating expense total

72.6 m88.5 m

EBIT

(72.3 m)(88.2 m)

EBIT margin, %

(24106%)(29405%)

Interest expense

(1.2 m)(1.1 m)

Interest income

231 k1.2 m

Net Income

(62.9 m)(73.5 m)(89.3 m)
$, USDFY, 2014FY, 2015FY, 2016

Cash

171 m201.6 m63.5 m

Accounts Receivable

155.5 m

Inventories

1.6 m1.6 m7.2 m

Current Assets

172.7 m254 m192.7 m

PP&E

19.3 m19.7 m10.6 m

Total Assets

192.5 m275.8 m204.4 m

Accounts Payable

3.1 m2.7 m3.8 m

Current Liabilities

10.2 m12 m19.6 m

Additional Paid-in Capital

435.1 m585.5 m598.6 m

Retained Earnings

(258.8 m)332.3 m(421.5 m)

Total Equity

253.3 m177.1 m

Financial Leverage

1.1 x1.2 x
$, USDFY, 2014FY, 2015FY, 2016

Net Income

(62.9 m)(73.5 m)(89.3 m)

Depreciation and Amortization

2.1 m2 m1.4 m

Inventories

(999 k)(192 k)(5.6 m)

Accounts Payable

(3.4 m)(692 k)953 k

Cash From Operating Activities

(55.1 m)(55.7 m)(59.8 m)

Purchases of PP&E

(7 m)(3.3 m)(1.7 m)

Cash From Investing Activities

(6.9 m)(56.3 m)(75.5 m)

Cash From Financing Activities

229.1 m142.6 m(2.6 m)

Interest Paid

1.2 m802 k676 k
$, USDY, 2016

Revenue/Employee

2.9 k

Financial Leverage

1.2 x

Revance Therapeutics Market Value History

Revance Therapeutics Company Life and Culture

You may also be interested in